All In Biotech

Drug Trial Radar · NCT07543458

Therapeutics for Moderate and Severe Dengue

A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 8,800 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

8,800

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Jul 31, 2030

Study completion Jul 31, 2031

Sponsor

Lead sponsor
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Oxford; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Number 2 Children's Hospital, Ho Chi Minh City; Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal; National Academy of Medical Sciences/Bir Hospital, Kathmandu, Nepal; Siriraj Hospital; Prince of Songkla University in Southern Thailand, Thailand; Dhaka Medical College; Chittagong Medical College and Hospital; Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia; Hospital Universitario Erasmo Meoz, Cucuta, Colombia; Fundación Valle del Lili, Cali, Colombia; Hospital Regional de Loreto, Iquitos, Peru; Instituto de Infectologia Emílio Ribas, São Paulo, Brazil; Universitas Sumatera Utara; Universitas Airlangga; University of Malaya; Hospital Queen Elizabeth, Malaysia; San Lazaro Hospital (SLH-NU), Manila, Philippines
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Conditions

  • Dengue
  • Severe Dengue
  • Mosquito-Borne Diseases
  • Vector Borne Diseases
  • Arbovirus Infections
  • Flavivirus Infections
  • RNA Virus Infections
  • Hemorrhagic Fever

Interventions

  • PlaceboDrug

    Placebo matched to baricitinib/dexamethasone in form, dose, frequency and duration.

  • DexamethasoneDrug

    Dexamethasone is a corticosteroid. Form: tablet or intravenous preparation. Dose: Aged ≥ 12 years: 6mg once daily. Aged 5 - 11 years by weight: * 10kg to \<20 kg: 2mg once daily, * 20kg to \<30 kg: 4mg once daily, * 30kg: 6mg once daily. Duration: 4 days, or until discharge if this happens before.

  • N-AcetylcysteineDrug

    N-acetylcysteine acts to protect the liver. It functions as a glutathione precursor and antioxidant. Dose: 100mg/kg/day, by continuous infusion over 24 hours in glucose 5% (preferred) or sodium chloride 0.9%. Duration: 4 days, or until hospital discharge if sooner.

  • Standard of careOther

    Standard of care as per local site guidelines

  • BaricitinibDrug

    Baricitinib is an inhibitor of Janus Kinase (JAK) 1 \& 2, and Numb associated kinase (NAK). Form: tablet. Dose: Aged ≥ 12 years: 4mg once daily, Aged 5 - 11 years: 2mg once daily. - Renal adjustment of dose: Adults: eGFR ≥30 and \<60 mL/min/1.73m2: 2mg once daily, eGFR ≥15 and \<30 mL/min/1.73m2: 2mg on alternate days. Children: eGFR ≥30 and \<60mL/min/1.73m2: 2mg on alternate days \- Dose should be halved in patients also taking probenecid Duration: 4 days, or less if the patient is discharged before this time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression to severe dengue/critical dengueTime frame: between randomization to hospital discharge (average of 5 days)
  2. All-cause mortality within 30 daysTime frame: Day 30

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • Chittagong Medical College Hospital

    Chittagong, Bangladesh

  • Dhaka Medical College & Hospital

    Dhaka, Bangladesh

  • Dhaka North City Corporation Hospital

    Dhaka, Bangladesh

  • Instituto de Infectologia Emílio Ribas

    São Paulo, Brazil

  • Centro de Atención y Diagnóstico de Enfermedades Infecciosas

    Bucaramanga, Colombia

  • Fundación Valle del Lili

    Cali, Colombia

  • Hospital Universitario Erasmo Meoz

    Cúcuta, Colombia

  • Universitas Sumatera Utara

    Medan, Indonesia

  • Hospital Queen Elizabeth II, Sabah

    Kota Kinabalu, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • National Academy of Medical Sciences/Bir Hospital

    Kathmandu, Nepal

  • Sukraraj Tropical and Infectious Disease Hospital

    Kathmandu, Nepal

  • Hospital Regional de Loreto

    Iquitos, Peru

  • San Lazaro Hospital

    Manila, Philippines

  • Siriraj Hospital, Mahidol University

    Bangkok, Thailand

  • Prince of Songkla University in Southern Thailand

    Songkhla, Thailand

  • Hospital for Tropical Diseases

    Ho Chi Minh City, Vietnam

  • Number 2 Children's Hospital

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.